Research · Sep 3, 2026
[RPRX] Royalty Pharma Thesis 2026: CF Royalty Anchor as Imbruvica Erosion Tests Acquisition Pipeline
Royalty Pharma navigated FY2025 with adjusted cash receipts roughly flat at ~$2.50B, as Vertex's cystic fibrosis franchise (Trikafta/Kaftrio) grew to ~$1.15B in royalties while Imbruvica declined to ~$360M on BTK inhibitor competitive pressure. Adjusted net income remained ~$2.05B on the royalty model's near-zero cost structure. The FY2026 thesis turns on whether $2B+ per year in new acquisitions can replace the Imbruvica/Spinraza cash flow decay with royalties from next-wave products in oncology, rare disease, and immunology — and whether Royalty Pharma can deploy at IRRs above 10% as competition for high-quality royalties intensifies.